V-Bio Ventures

Dualyx specializes in the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company focuses on creating immune modulators, particularly Treg-targeted therapies, which are designed to suppress unwanted autoimmune reactions in patients. By advancing these innovative treatments, Dualyx aims to provide lasting solutions for individuals suffering from autoimmune diseases, ultimately enabling medical professionals to offer effective cures.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly those experiencing worsening and acute decompensated heart failure. The company focuses on addressing unmet medical needs in this area and aims to provide effective treatments that enhance understanding of the underlying disease biology. Additionally, Corteria's research extends to related conditions such as sarcopenia and obesity, positioning the company to make a significant impact on the management of these interconnected health issues.

Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.

Operator of a biopharmaceutical company intended to discover and develop therapies that slow or stop the progression of neurodegenerative diseases. The company engages in identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia, and Parkinson's, enabling people suffering from neurodegenerative diseases to access suitable therapeutics for fast recovery.

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Precision Ocular Metrology is a medical device startup dedicated to revolutionizing the way we measure ocular surface topography. Standard Placido disk slope measurements are great for optical power measurements on the central regions of the cornea but provide poor elevation topography, making them poor choices for specialty lens fitting. Our sMap3D topographer addresses this problem by providing direct anterior surface elevation measurements, letting you map the complete three-dimensional eye surface with an unprecedented 10 um precision.

Aphea.Bio NV/SA, founded in 2017 and headquartered in Gent, Belgium, specializes in the manufacture of biopesticides and biostimulants aimed at promoting sustainable agriculture. The company focuses on developing next-generation biopesticides derived from natural microorganisms, providing alternatives to traditional chemical pesticides, which face increasing regulatory scrutiny. Additionally, Aphea.Bio creates innovative biostimulants that enhance crop growth by improving nutrient uptake from the soil. Its products are designed to increase crop yields and protect against specific fungal diseases, contributing to more sustainable farming practices.

Animab BV, a biotechnology company, develops monoclonal antibodies for livestock. It develops mimic secretory IgA, a type of natural antibody passed through colostrum and milk to protect nursing animals. The company will help swine producers with antibiotics for the control of gastrointestinal pathogens. Animab BV was incorporated in 2020 and is based in Ghent, Belgium.

Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.

Biodol Therapeutics SAS, founded in 2015 and located in Clapiers, France, focuses on developing innovative treatments for chronic pain. The company has identified the receptor tyrosine kinase FLT3 as a critical factor in triggering and sustaining chronic neuropathic pain. Through its proprietary approach, Biodol Therapeutics develops extracellular inhibitors of the FLT3 receptor, which aim to inhibit ligand binding and thereby alleviate conditions such as allodynia, pain hypersensitivity, and spontaneous pain without disrupting normal nervous system function. Additionally, research partnerships have indicated that inhibiting FLT3 may enhance the efficacy of opioids, potentially reducing their associated risks, including addiction. This innovative work positions Biodol Therapeutics as a significant player in addressing chronic pain and contributing to solutions for the opioid crisis.

ExeVir Bio BV is a Belgium-based biotechnology company established in 2020, focused on developing single-domain antibody therapies to combat viral infections. The company utilizes a llama-derived antibody technology platform, specifically the VHH technology, to create robust antiviral treatments that offer broad protection against coronaviruses, including SARS-CoV-2. ExeVir's lead candidate, VHH72-FC, targets a conserved region on the virus's spike protein essential for cellular entry. This innovative approach not only aims to provide effective treatment and prevention strategies for viral infections but also enables rapid development of drug candidates in response to emerging health threats, ensuring stability and cost-effectiveness for global access. ExeVir Bio's therapies are designed to reduce viral load and inflammation, thereby supporting immune responses and protecting vulnerable populations, including healthcare workers and individuals with co-morbidities.

Orionis Biosciences operates in the healthcare industry focusing on the biotechnology business and innovation. The company is an early-stage drug discovery and development biotechnology company fueled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical needs – with an initial internal focus in oncology and immunotherapies. Orionis Biosciences has research facilities in the Boston area (Headquarters in Waltham, MA, USA) and Ghent (Belgium), and is operated by a world class team of entrepreneurs, scientists and transatlantic network of investors, in concert with strategic research and development collaborations. The latter includes collaborations with VIB (Belgium), Orionis Biosciences co-founding institution.

RootWave develops and distributes machinery that kills weeds in the agricultural lands. It offers hand weeders for growers, gardeners, and groundskeepers to spot weed and treat invasive species; and solutions for automating weeding in agriculture using visual recognition and to target weeds in arable crops. The company sells its products through distributors in France, Australasia, Ireland, and South Korea. RootWave was founded in 2012 and is based in Kineton, United Kingdom.

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients with Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two primary drug discovery programs aimed at identifying selective HDAC6 inhibitors and GABABR1a agonists. These compounds are designed to offer neuroprotection against nerve degeneration and to promote the repair of peripheral myelin. Through its research and development efforts, Augustine Therapeutics aims to enhance the quality of life for patients afflicted with these challenging neurological conditions.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO® technology, Confo Therapeutics stabilizes inherently unstable functional conformations of GPCRs, providing a robust starting point for drug discovery. This approach reveals previously inaccessible structural features of these receptors, facilitating the identification of novel agonists that enhance therapeutic interventions.

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.

Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.

Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.

Aphea.Bio NV/SA, founded in 2017 and headquartered in Gent, Belgium, specializes in the manufacture of biopesticides and biostimulants aimed at promoting sustainable agriculture. The company focuses on developing next-generation biopesticides derived from natural microorganisms, providing alternatives to traditional chemical pesticides, which face increasing regulatory scrutiny. Additionally, Aphea.Bio creates innovative biostimulants that enhance crop growth by improving nutrient uptake from the soil. Its products are designed to increase crop yields and protect against specific fungal diseases, contributing to more sustainable farming practices.

Octimet Oncology NV is a biotechnology company based in Beerse, Belgium, established in 2016. The company focuses on developing MET kinase inhibitors and other selective anti-tumor molecules aimed at treating various types of cancer. Octimet employs innovative patient selection and pharmacodynamic biomarker-based strategies to enhance the development of its discovery-stage molecules. By utilizing these advanced methods, Octimet aims to differentiate its treatments from existing options in the market, ensuring that patients receive targeted therapies for solid tumors. The company's strategic approach emphasizes clinical development that leverages biomarker-defined intelligent patient selection, ultimately striving to improve treatment outcomes for cancer patients.

Precision Ocular Metrology is a medical device startup dedicated to revolutionizing the way we measure ocular surface topography. Standard Placido disk slope measurements are great for optical power measurements on the central regions of the cornea but provide poor elevation topography, making them poor choices for specialty lens fitting. Our sMap3D topographer addresses this problem by providing direct anterior surface elevation measurements, letting you map the complete three-dimensional eye surface with an unprecedented 10 um precision.

Orionis Biosciences operates in the healthcare industry focusing on the biotechnology business and innovation. The company is an early-stage drug discovery and development biotechnology company fueled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical needs – with an initial internal focus in oncology and immunotherapies. Orionis Biosciences has research facilities in the Boston area (Headquarters in Waltham, MA, USA) and Ghent (Belgium), and is operated by a world class team of entrepreneurs, scientists and transatlantic network of investors, in concert with strategic research and development collaborations. The latter includes collaborations with VIB (Belgium), Orionis Biosciences co-founding institution.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO® technology, Confo Therapeutics stabilizes inherently unstable functional conformations of GPCRs, providing a robust starting point for drug discovery. This approach reveals previously inaccessible structural features of these receptors, facilitating the identification of novel agonists that enhance therapeutic interventions.